Showing 1291-1300 of 5603 results for "".
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
https://reachmd.com/programs/cme/clinical-criteria-and-imaging-strategies-for-b7-h3directed-adcs-in-es-sclc/39977/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Targeting CKD-aP at the Source: Key Mechanisms and Treatments
https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/Explore CKD-associated pruritus mechanisms, clinical impact, and evidence-based treatments, including kappa-opioid receptor agonists.Brain Metastases Management: From Detection to Multidisciplinary Care
https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
https://reachmd.com/programs/cme/case-based-approach-managing-hyperkalemia-in-patients-with-ckd-and-heart-failure/37617/Explore expert tips on using potassium binders to manage hyperkalemia and maintain GDMT in patients with CKD and heart failure.Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerSafety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerClinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Safety in oHCM Therapy: How and When to Transition Treatment?
https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.